Next Generation Sequencing (NGS) tests are capable of rapidly identifying or ‘sequencing’ large sections of a person’s genome and are important advances in the clinical applications of precision medicine.
Patients, physicians and researchers can use these tests to find genetic variants that help them diagnose, treat, and understand more about human disease.
Next-generation sequencing (NGS), also known as high-throughput sequencing, is a revolutionary technology used in genomics to sequence DNA and RNA quickly and at a massive scale. NGS has dramatically transformed the field of genomics, making it possible to decipher the genetic information of various organisms with unprecedented speed and accuracy. Here are some key aspects of next-generation sequencing:
Parallel Sequencing: NGS allows for the parallel sequencing of millions of DNA fragments or RNA molecules simultaneously. This high-throughput approach is in contrast to traditional Sanger sequencing, which is a slower and more labor-intensive method.
Applications: NGS has numerous applications in genomics, including:
Genome Sequencing: Determining the entire DNA sequence of an organism’s genome.
Exome Sequencing: Focusing on the coding regions (exons) of genes, which are responsible for protein production.
RNA Sequencing (RNA-Seq): Analyzing the transcriptome, which is the complete set of RNA molecules in a cell, tissue, or organism.
Metagenomics: Studying the genetic material of microbial communities in environmental samples.
Epigenomics: Investigating epigenetic modifications like DNA methylation and histone modifications.
ChIP-Seq: Identifying protein-DNA interactions by combining chromatin immunoprecipitation with sequencing.
Targeted Sequencing: Focusing on specific genomic regions or genes of interest.
Platforms: Several NGS platforms are available, each with its own sequencing technology and chemistry. Common NGS platforms include Illumina, Ion Torrent (Thermo Fisher), Pacific Biosciences (PacBio), and Oxford Nanopore Technologies.
Data Analysis: NGS generates massive amounts of raw data in the form of short DNA sequences (reads). Data analysis involves aligning these reads to a reference genome (in the case of genome sequencing), identifying variations (e.g., SNPs), and extracting meaningful biological insights.
Cost and Speed: NGS has significantly reduced the cost of sequencing DNA, making it accessible for a wide range of research applications. It also allows for rapid sequencing, enabling projects that were previously time-prohibitive.
Challenges: NGS is not without its challenges. Handling and analyzing the massive amount of data generated can be computationally intensive. Quality control and error correction are crucial to ensure accurate results. Additionally, long-read technologies, like PacBio and Oxford Nanopore, have emerged to address some limitations of short-read NGS, such as the inability to sequence long repetitive regions accurately.
Advancements: Since its introduction, NGS technologies continue to evolve. Innovations have led to improvements in read length, accuracy, and throughput, enabling a broader range of genomics research.
Next-generation sequencing has had a profound impact on biology and medicine. It has been instrumental in advancing our understanding of genetics, genomics, and the molecular basis of various diseases. It has also facilitated personalized medicine, allowing for tailored treatment plans based on an individual’s genetic makeup.
Next Generation Sequencing (NGS) Tests within the In Vitro Diagnostics therapeutic area proves invaluable. The in-depth report provides a detailed examination of the impact of market trends on NGS Tests, a cutting-edge technology that allows an entire genome to be sequenced at once. Its use in whole-genome sequencing, exome sequencing, transcriptome sequencing, and targeted sequencing of multi-gene panels is becoming increasingly standard.
The utilization of NGS Tests in identifying key mutations is a significant pivot in the personalization of treatments. Its increasing usage in evaluating tumor biopsies for a wide range of targetable mutations only attests to NGS Tests’ potential in transforming the healthcare industry. The report offers an unparalleled view into the current market scenario, covering 39 countries complete with color-coded, fully-sourced market models highlighting epidemiology-based indications, procedure volumes, and more. The model also provides crucial insights into the competitive dynamics of the NGS Tests sector, and in-depth country-specific overviews of healthcare systems, reimbursement policies, and medtech regulatory landscapes. With this comprehensive guide, CMO executives, sourcing and procurement leaders, and private equity investors can make better-informed strategic decisions in a high-potential market.
Next Generation Sequencing (NGS) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on NGS Tests market for the year 2020 and beyond. NGS allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. NGS can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.
It is now standard to test for a high number of mutations to personalize treatment decisions, use of NGS panels that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing. NGS is routinely being used to identify KRAS, BRAF, EGFR, ALK, BRCA and HER2 mutations.
This model includes Next Generation Sequencing (NGS) Tests.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
https://www.thermofisher.com/us/en/home/life-science/sequencing/next-generation-sequencing.html